Celularity Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company has 180 days to raise its stock price or it may be removed from Nasdaq, making shares harder to buy and sell.
The company needed emergency cash with a 4% interest rate, but rates jump to 18% if payments are missed.
New chief operating officer and chief legal officer signal leadership focus on finance and strategy as company restructures.
Another Nasdaq rule violation gives company 180 days to recover or face potential removal from the stock exchange.
New sales leader hired to push cenplacel-L product and Lifebank platform, showing company focus on generating revenue.
Company restructures major obligation by trading preferred stock and promissory note for $1 million in spread-out payments.
Full-year financial statements show company performance and are required for all public companies annually.
Stocky reads Celularity Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Celularity Inc.'s most recent tracked filing was a 8-K on 29 Jul 2026: Stock price falls below $1.00, faces delisting warning.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.